DNA-guided Second Line Adjuvant Therapy for High Residual Risk, Estrogen Receptor Positive, HER-2 Negative Breast Cancer (DARE)

NCT04567420 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

70

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Cancer

Interventions

DRUG: Palbociclib
DRUG: Fulvestrant
DRUG: Adjuvant Therapy

Sponsor

Criterium, Inc.